JAMP-ASA EC 80 MG
ACETYLSALICYLIC ACID : 80 MG · DIN 02283905 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP-ASA EC?
JAMP-ASA EC 80 MG contains ACETYLSALICYLIC ACID : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02283905, held by JAMP PHARMA CORPORATION, supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Oct-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02283905 |
|---|---|
| Brand name | JAMP-ASA EC |
| Generic / active ingredient | ACETYLSALICYLIC ACID : 80 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 80 MG |
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | N02BA01 ACETYLSALICYLIC ACID |
| AHFS class | 28:08.04.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Oct-2020 |
| Original market date | 2006-09-28 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N02BA01 ACETYLSALICYLIC ACID. 15 of 146 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ASA 325MG | 325 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 00530336 |
| ASAPHEN | 80 MG | TABLET (CHEWABLE) | PHARMASCIENCE INC | MARKETED | DIN 02009013 |
| ASAPHEN E.C. 80 MG | 80 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02238545 |
| ASPIRIN COATED FOR DELAYED RELEASE REGULAR STRENGTH | 325 MG | TABLET (DELAYED-RELEASE) | BAYER INC | MARKETED | DIN 02150417 |
| ASPIRIN EXTRA STRENGTH | 500 MG | TABLET | BAYER INC | MARKETED | DIN 02150336 |
| ASPIRIN REGULAR STRENGTH | 325 MG | TABLET | BAYER INC | MARKETED | DIN 02150328 |
| JAMP-ASA CHEW | 80 MG | TABLET (CHEWABLE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02269139 |
| M-ASA 80 MG CROQUABLE | 80 MG | TABLET (CHEWABLE) | MANTRA PHARMA INC | MARKETED | DIN 02429950 |
| PRO-AAS - 80 (CROQUABLE) | 80 MG | TABLET (CHEWABLE) | PRO DOC LIMITEE | MARKETED | DIN 02311518 |
| PRO-AAS EC - 80 | 80 MG | TABLET (DELAYED-RELEASE) | PRO DOC LIMITEE | MARKETED | DIN 02311496 |
Who else supplies ACETYLSALICYLIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ACETYLSALICYLIC ACID appears in 11 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.